Web Exclusives

Chicago, IL—Treatment with the immune checkpoint inhibitor pembroliz­umab (Keytruda) dramatically improved 5-year survival for patients with advanced non–small-cell lung cancer (NSCLC) compared with expected survival in the preimmunotherapy era, according to the 5-year follow-up data from the phase 1b KEYNOTE-001 clinical trial. The study was presented at ASCO 2019 and was published simultaneously in the Journal of Clinical Oncology. Read More ›

Ovarian cancer not only exacts a high mortality rate, but also affects the physical, mental, and financial health of those diagnosed with the disease. Read More ›

Epidemiologic studies reveal population-based disparities in ovarian cancer morbidity and mortality rates. Read More ›

Genetic, menstrual, and other factors have been associated with increased risk of ovarian cancer. Read More ›

Current screening practices for ovarian cancer continue to result in late-stage diagnoses with consequent poor prognoses. Read More ›

On November 15, 2019, the FDA approved crizanlizumab (Adakveo; Novartis) to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged ≥16 years with sickle-cell disease.

Read More ›

• Calquence Receives FDA Approval for the Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
• Despite Some Positive Trends, Report Confirms Lung Cancer Remains the Deadliest Form of Cancer

Read More ›

• Teva Will Resume Production of Vincristine in Response to Shortage
• FDA Fast-Tracks Opdivo plus Yervoy Regimen for Treatment of Advanced Liver Cancer
• FDA Grants Accelerated Approval to Brukinsa for Patients with Mantle-Cell Lymphoma

Read More ›

New research sponsored by the National Cancer Institute showed that patients with Medicaid or with no insurance had significantly worse overall survival in clinical trials compared with commercially insured patients. Read More ›

• FDA Approves Ziextenzo, Third Biosimilar to Pegfilgrastim for Febrile Neutropenia
• Trump Will Nominate Dr Hahn as Next FDA Commissioner
• Researchers Report High Rates of E-Cigarette Use Among Children and Teens

Read More ›